Coronavirus (COVID-19) Pandemic: What the Nuclear Medicine Departments Should Know

Gopinath Gnanasegaran¹, Hian Liang Huang², Jessica Williams³, Jamshed Bomanji²,³

¹Dept of Nuclear Medicine, Royal Free London NHS Foundation Trust, Pond Street, London NW3 2QG, UK and ²Institute of Nuclear Medicine, University College London Hospital, 235 Euston Road, London NW1 2BU and ³HCA Healthcare UK, Harley Street Clinic, London England W1G 7LK

Correspondence
Prof Jamshed Bomanji
Institute of Nuclear Medicine,
University College London Hospital,
235 Euston Road, London NW1 2BU
jamshed.bomanji@nhs.net

Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/.
Details: http://jnmt.snmjournals.org/site/misc/permission.xhtml.
**Introduction**

The new coronavirus (COVID-19-coronavirus 2019-nCoV-/SARS-CoV-2) pneumonia was first reported in Wuhan, China, in December 2019, and it was extracted from the lower respiratory tract samples of humans (1). The World Health Organization officially announced COVID-19 viral disease as pandemic on 11th March 2020 (2).

The COVID-19 virus is spreading rapidly despite precautions. The most common symptoms include severe pneumonia (fever, dry cough, dyspnoea), and fatigue (1) Sore throat, headache, loss of taste and smell, rhinorrhoea, and diarrhoea can occur uncommonly (1). Lymphopenia is commonly seen in patients with COVID-19 (3,4). The mean incubation is reported to be 5.2 days, and transmission can occur during the incubation period in asymptomatic patients (5). COVID-19 is reported to be transmitted via respiratory droplets and fomites during unprotected close contact with an infected individual (6,7).

The COVID-19 viral infection spread is reported from 212 countries and regions (2). Throughout history, humans have encountered several epidemics and pandemics, and several of them have changed the course of history. Pandemics increase morbidity and mortality and cause significant economic, political, and social disruptions in a negative way (8).

The aim globally is to encourage social (physical) distancing to slow the disease transmission and to avoid increased strain on the local health care systems. The significant health care challenges would be in the production, supply, and availability of equipment for caring patients and staff during this pandemic. A coordinated response and responsibility should be emphasized and implemented on time to maintain public health
awareness and information, reduction of transmission, and care for and treatment of the patients with COVID-19 (2). Despite this, significant gaps, misunderstandings, and challenges exist in fighting global pandemic preparedness. To compound this further, the guidance and recommendations are rapidly changing, as new evidence emerges and evolves. Local policy should be adopted in consensus with national and international recommendations. People must follow the local government or department of health recommendations and restrictions.

Hospitals and departments should have the standard operating procedure (SOP) in place for staff imaging patients suspected or confirmed with COVID-19 infection and systems in place to ensure these are regularly updated. This article is based on the currently available literature, and the purpose is to discuss and review precautions and safety measures for nuclear medicine department staff to manage patients with known or suspected COVID-19 disease. The situation is changing rapidly, and there is every chance that discussion from this article will change over the coming days and weeks. Secondly, the responsibility lies with each institution or hospital to ensure their written policy adheres to that outlined by National Public Health Guidance in their respective countries.

**Coronavirus**

COVID-19 is an abbreviation for coronavirus disease-2019 and is a novel beta coronavirus (1). Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the name that has been given to the 2019 novel coronavirus with COVID-19 being the name of the disease (2). Coronavirus belongs to the family of coronaviridae family and is an
enveloped positive-strand RNA virus (1,9). Coronaviruses are named for the crown-like spikes on their surface (9, 10). The most likely origin of COVID-19 is zoonotic, given it has a genome identity of 96% to a bat SARS-like coronavirus (6,11). COVID-19 virus has been detected in respiratory, faecal, and blood specimens of infected patients (6,11). COVID-19 virus is reported to remain viable as an aerosol for up to 3 hours (12). There are reports that SARS-CoV-2 transmission can occur via ocular surfaces as infected droplets and bodily fluids might contaminate the human conjunctival epithelium (13). COVID-19 virus was reported to be found in upper respiratory samples, 1–2 days before the onset of symptoms (14) and is thought to be mainly spread via asymptomatic carriers (5,15,16).

**Nuclear Medicine: Staff and patient**

World Health Organization (WHO) recommends respiratory protection with the use of a standard medical mask (17,18). In terms of personal protective equipment (PPE) WHO recommends contact and droplet precautions which include: wearing disposable gloves to protect hands; clean, non-sterile, long-sleeve gown to protect clothes from contamination; medical masks to protect nose and mouth; and eye protection (e.g., goggles, face shield), before entering the room of a suspected or confirmed COVID-19 patient (17,18) Respirators (e.g. N95) are recommended for aerosol generating procedures(17). With the increasing cases and shortage of testing kits for COVID-19, there should be greater emphasis on infection control and social distancing measures for both public and staff members in the healthcare environment. Effective and efficient use of both staff and equipment in nuclear medicine departments is crucial for patient care.
and workplace safety. There are numerous measures reported from several national and international bodies, which could be implemented nationally and regionally (2,17,18,19). However, the policies and their implementation will vary from region to region. Departments should be aware of their national or local hospital policies and follow them accordingly. There are numerous articles related to radiology procedures, but there is limited advice and information related to nuclear medicine service. Compared to conventional imaging, the requirements and logistics for the nuclear medicine departments are relatively complex, such as scheduling appointments, patient contact, regulatory compliance, prioritizing procedures, duration of the scans, and infection controls are similar (20-25) (Table 1). Our top priorities should be (a) ensuring personal wellness of our staff and (b) provide sufficient training and staff cover to manage patients with suspected or confirmed COVID-19 infection.

The team should be made aware of the fact that there are asymptomatic carriers of the virus, and good contact history is of use. We should also ensure, the patients have access to alcohol gel, hand washing facilities, tissue boxes, and masks in the waiting areas. Nuclear medicine reception staff should self-protect and be vigilant at all times and encourage the patient to self-declare if they or any family members have any symptoms or have recently travelled from places affected with COVID-19 infection. The staff should ask specific and direct questions such as a history of fever, dry cough, dyspnoea, and fatigue. Patients should be encouraged to follow basic hygiene practices (26). The patient waiting area should be large enough so patients can maintain distance while
seated or schedule the patient appointments accordingly to avoid too many patients using the waiting area at a given time.

In general, the nuclear medicine staff, which includes technologists, nurses, and healthcare assistants, are at the risk of exposure to COVID-19. Nuclear medicine procedures require radiotracer injection, unlike radiological procedures, and staff contact is essential. In the majority of cases, nuclear medicine procedures are outpatient-based, and in limited circumstances are in-patient based. In-patients will be a combination of oncology and non-oncology patients. There is a probability that patients with COVID-19 infection may be asymptomatic at the time of attending the department for the scans. Furthermore, not all in-patients may be tested for COVID-19 before they are sent to the department for scans. These scenarios pose a risk for all staff from reception to the scanning room. In general, most nuclear medicine scanners are not portable types of machinery like the x-ray or ultrasound, and therefore, patients attending the department for scans is inevitable. Consequently, we should have a stringent mechanism in place to protect our staff and patients, and contingency plan for the temporary absence of staff from illness and quarantine which might affect regular work in the department.

In the current circumstances, most departments based in hospitals which are COVID-19 hubs are postponing routine elective scans, while continuing to provide urgent nuclear medicine scans (e.g. PET-CT scans for oncology patients) [Table 2-4]. Given widespread transmission and increased risk of asymptomatic patients, staff should use personal protective equipment according to the local policy. The PPE items must be donned before entering the patient area and the donning and doffing procedure should
be performed correctly. In general, the team should minimize the number of staff in each clinical encounter to reduce unnecessary movement in and out of injection or scanning rooms, and PPE should be worn while escorting the patients.

Airborne transmission of COVID-19 continues to be debated. There is an ongoing dilemma of whether or not to do ventilation and perfusion scans (VQ scans). It is reported that airborne viruses can spread in air conditioning and ventilation systems. Medical procedures associated with the generation of aerosols, such as ventilation scans and oxygen supplementation, might carry an increased risk of transmission. Therefore, some have suggested stopping VQ scan service due to an aerosol-based ventilation scan. Secondly, the use of perfusion only scans are unlikely to be of any benefit if COVID-19 infection is suspected (COVID-19 response might alter the MAA distribution) (20).

Others have proposed several alternatives, such as (a) performing only perfusion imaging (e.g. pregnant patients) or (b) Perfusion SPECT or SPECT-CT. Overall, it depends on the local conditions, and decisions should be made based on national or regional policies (22), and special precautions, especially for personnel conducting these tests must be taken. A chest x-ray should be mandatory before performing a VQ scan. The current reports suggest asymptomatic COVID-19 carriers may have positive chest X-rays after 14 days of quarantine, even with no RT-PCR (Reverse Transcription Polymerase Chain Reaction) testing for COVID-19 (27). The Chest x-ray findings in COVID-19 patients are reported to frequently show bilateral lower zone consolidation (peaked at 10-12 days from symptom onset) (28).
**Nuclear Medicine: Radionuclide therapies**

Nuclear Medicine departments perform various radionuclide therapies for both benign and malignant disease. The hospital and department providing these services should have a practical and realistic solution. The multidisciplinary team must make a pivotal decision. The radionuclide therapy service depends on multiple factors such as (a) out-patient or in-patient treatments, (b) availability of beds for in-patient based treatments (c) regular supply/delivery of radiopharmaceuticals, (d) risk of a patient contracting COVID-19 during the hospital stay, (e) staff skill mix (in case therapy staff is infected with the virus), (f) robust selection criteria, and (g) treating elderly cancer patients with co-morbidities. Finally, when patients are treated, they should additionally consent for risk of COVID-19 infection during their stay in the hospital, and the need for radionuclide therapy should balance against the risk of contracting COVID-19 disease (Table 4).

**Nuclear Medicine: Social distancing**

Social isolation or distancing is crucial to prevent transmission from asymptomatic carriers. In the scan reporting rooms, it is suggested that the workstations should be separated at least 6 feet apart (23,24,25). The department should consider providing alternative technological solutions for Nuclear Medicine consultants and residents for distant(remote) or off-site working (e.g., reporting scans, protocolling procedures). Secondly, multidisciplinary meetings or case discussions should be web-based/teleconferencing (23,24,25). Several departments have opted for flexible rota or schedules, e.g., by working in small-teams or with one week on-site and 1-week remote
working. Establishing a group email or social media to keep in touch and communicate effectively is essential.

**Nuclear Medicine: Imaging equipment**

Local hospitals should have clear policies and procedures in place for nuclear medicine staff imaging suspected or confirmed COVID-19 patients. The department and/or healthcare system SOP should be updated regularly following the evolving evidence. Van Doremalen et al (12) have studied how long the virus survives in the air and on surfaces (plastic, stainless steel, copper, and cardboard). They have confirmed that SARS-CoV-2 remained active on plastic and stainless steel surfaces for 48-72 hours, cardboard for 24 hours, and four hours on copper (12). However, these times will vary under real-world conditions and might depend on the temperature, humidity, ventilation, and the amount of virus deposited (12).

The most important questions related to nuclear medicine include clean imaging techniques and decontamination of imaging equipment (e.g SPECT-CT, PET-CT scanners) in addition to any surface that may have come into contact with respiratory droplets. In general, after the patients are scanned, the scanner and room surface should be disinfected to prevent the potential spread, and appropriate training of environmental maintenance staff is recommended (20) [Figure 1]. Public Health England has published guidance “COVID-19: cleaning in non-health care settings”. The risk of infection depends on several factors such as (a) the type of surfaces contaminated (b) the amount of virus shed from the individual (c) the time the individual spent in the setting and (d) the time since the individual was last in the environment (29). All surfaces that the symptomatic
person might have come into contact with must be cleaned and disinfected (e.g., visible body fluids, imaging equipment, chair, bathrooms, door handles, telephones, grab-rails in corridors and stairwells) (29). The PPE should be worn for cleaning an area where a person with possible or confirmed COVID-19 attends (29). Public Health England recommends the use of either a combined detergent disinfectant solution at a dilution of 1,000 parts per million available chlorine or if an alternative disinfectant is used within the organization, this should be checked to ensure that it is effective against enveloped viruses (29).

The British Society of Thoracic Imaging (BSTI) has produced action cards to assist with designing local radiology standard operating procedures for patients who have or are at risk of COVID-19 and could apply to nuclear medicine departments (e.g., Transfer of a patient to CT; performing a CT scan etc. (30). However, these are examples only, and responsibility lies with each institution or hospital to ensure their written policy adheres to their National Public Health Guidance in their respective countries.

**Nuclear Medicine: Radiopharmaceuticals**

The functioning of Nuclear Medicine procedures depends on the availability of radioisotopes and kits. These are not always locally produced, and the Nuclear Medicine centres rely on an external supply from national and international supply and distribution channels. In the current scenario, with land and air traffic lockdowns, a shortage of radioisotopes and kits is expected, and it is difficult to predict when and for how long. For efficient use of kits, block booking of specific procedures should be envisaged. Alternately, PET-CT scans can be used in some indications (e.g., Bone imaging with 18F-
NaF, Infection imaging with 18F-FDG, etc.) in place of single isotope methods. Myocardial Perfusion Imaging could be performed as a one-day protocol (stress/rest). The local nuclear medicine departmental managers or radiopharmacists should contact the suppliers and update the local team to plan bookings accordingly. In comparison to SPECT service, the PET centres with local cyclotrons might continue to function as usual in most cases. For departments without cyclotrons, the availability of FDG will depend on local conditions.

**Nuclear Medicine: Staff well being**

The current scenario might cause psychological distress, social, and financial insecurity. Staff coming to work at the hospital have concerns that they might contract the virus and expose their friends or family members. We should make an effort to provide relevant and reliable information to allay their fears (e.g., social distancing, infection control, self-quarantine, etc.). There should be specific local guidelines for viral testing of staff returning to work after illness. The team should remain connected with each other or with their friends and families via group email or in-portals/social media etc.

**Nuclear Medicine: Continuing Medical Education (CME) and Continuing Professional Development (CPD)**

Departments who are active in teaching and training could use on-line teaching material and webinars, which are available from most national and international nuclear medicine societies, which could be an alternative to face to face interaction and learning. National organizations should make some of their on-line education material available free for its
members. Research work will be challenging during the current circumstances (except research related to COVID-19 infection) as most institutions have suspended their projects, and alternative ways of collaborating should be envisaged to prevent disruption of vital projects (23,25).

**Nuclear Medicine: Chest imaging findings in PET-CT & SPECT-CT**

Incidental parenchymal lung abnormalities have been reported in patients with COVID-19, and prompt recognition may be useful for timely isolation and treatment (1) [Fig2-5].

Chest X-ray and CT appearances of COVID-19 are reported to have significant overlap with previous coronavirus infections (31-33).

Chest CT is reported to be an essential component in the diagnostic algorithm for patients with suspected COVID-19 infection (32,33). The reported sensitivity of chest CT in detecting COVID-19 at the initial presentation is 56-98% during the early stages of disease development (34,35), and the specificity was low (25%) (36).

Chest CT is found to have limited sensitivity and negative predictive value early after symptom onset and is unlikely to be used as a reliable independent tool to rule out COVID-19 infection (32).

The initial findings in infected patients from Wuhan have shown bilateral lung opacities. The typical features include lobular and subsegmental areas of consolidation (31,32). Other groups have reported high rates of ground-glass opacities and consolidation, and sometimes with a rounded morphology and peripheral lung distribution (31,37). The more extensive disease is reported to be seen on the CT approximately ten days after the onset of symptoms (37).
The frequency of CT findings is related to the infection time course (31,32), and based on the current evidence, there are ground-glass abnormalities in the early disease phase, followed by crazy paving and increasing consolidation later in the disease course (32,37). Multifocal involvement is reported to be common, and the CT signs gradually improve approximately 14 days of post-symptom onset (31,32,36,37).

The hallmark of COVID-19 infection on CT is ground-glass and consolidation/ pulmonary opacities (often with a bilateral and peripheral lung distribution) (31,32). Bernheim A et al. have reported the absence of ancillary CT findings such as pleural effusions, lung cavitation, pulmonary nodules, and lymphadenopathy (31,32). Bai HX et al. have assessed the performance of the United States (U.S.) and Chinese radiologists in differentiating COVID-19 from viral pneumonia on chest CT and found high specificity but moderate sensitivity (38). The British Society of Thoracic Imaging has published a reporting guidance and proforma, which might help to report them with speed and accuracy (39) and have published a teaching library. Its content will be accessible without log-on via the BSTI website (39). COVID-19 suspected pneumonia is FDG-avid and might be detected as an incidental finding in asymptomatic patients undergoing PET-CT (40). Nuclear Medicine community should be vigilant to look for other unexpected scan findings which might reflect the effects of COVID-19 exposure/infection.

**Conclusion**

COVID-19 infection has changed the way we work. We should stay informed and support each other and provide practical solutions for safety and social wellbeing during these uncertain times. We should adhere to our National and International recommendations.
The healthcare system and professionals must aim to deliver safe patient care, workplace safety, and personal wellness. “Life imposes things on you that you can’t control, but you still have the choice of how you’re going to live through this.” — Celine Dion

**Acknowledgments:** To all Medical and Nuclear Medicine Professionals worldwide for their dedication and commitment to publish numerous documents and share their experience to fight COVID-19.

**Conflict of Interest:** All authors declare no conflict of interest.
References:

1. Huang C., Wang Y., Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506

2. Rolling updates on coronavirus disease (COVID-19) www.who.int

3. Guan W.-J., Ni Z.-Y., Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020:1–13.

4. Chen N., Zhou M., Dong X. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513.

5. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China 2019. N Engl J Med. In press

6. Aylward Bruce, (WHO), Liang W., (PRC) 2020;2019(February). Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) pp. 16–24.https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf

7. Tan W, Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease [published online ahead of print, 2020 Mar 28]. Int J Cardiol. 2020;S0167-5273(20)31593-X.

8. Madhav N, Oppenheim B, Gallivan M, et al. Pandemics: Risks, Impacts, and Mitigation. In: Jamison DT, Gelband H, Horton S, et al., editors. Disease Control Priorities: Improving Health and Reducing Poverty. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 27. Chapter 17. Available from: https://www.ncbi.nlm.nih.gov/books/NBK525302/doi.

9. Weiss, S.R., Leibowitz, J.L. Coronavirus pathogenesis. Adv Virus Res. 2011;81:85–164).

10. Centers for disease control and Prevention Content source: National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases.(CDC.gov )

11. Wan Y., Shang J., Graham R. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J. Virol. 2020;(March):1–9

12. van Doremalen N., Bushmaker T., Morris D.H. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N. Engl. J. Med. 2020
13. Lu C-W, Liu X-F, Jia Z-F. 2019-nCoV transmission through the ocular surface must not be ignored. The Lancet. 2020;395:e39. https://doi.org/10.1016/s0140-6736(20)30313-5

14. Yang H. The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): a Chinese perspective. J. Med. Virol. 2019;1:0–2. doi: 10.1002/jmv.25749.

15. Bai Y., Yao L., Wei T. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020 Feb;21:19–2

16. Mizumoto K., Kagaya K., Zarebski A. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Eurosurveillance. 2020;25(10):2000180.

17. World Health Organization. Rational use of personal protective equipment for coronavirus disease 2019 (COVID-19). 2020, February 27, https://apps.who.int

18. Centers for Disease Control and Prevention. Interim infection prevention and control recommendations for patients with confirmed coronavirus disease 2019 (COVID-19) or persons under investigation for COVID-19 in healthcare settings. 2020, February https://www.cdc.gov/coronavirus

19. Rutala WA, Weber DJ and the Healthcare Infection Control Practices Advisory Committee (HICPAC) Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008 https://www.cdc.gov/infectioncontrol/guidelines/disinfection/

20. Huang HL, Allie R, Gnanasegaran G, Bomanji J. COVID19 -Nuclear Medicine Departments, be prepared! Nucl Med Commun. 2020 Apr;41(4):297-299.

21. Skali H ; Murthy VL.; Al-Mallah MH et al Guidance and Best Practices for Nuclear Cardiology Laboratories during the Coronavirus Disease 2019 (COVID-19) Pandemic: An Information Statement from ASNC and SNMMI.

22. Notghi A, Pandit M, O’Brien J , Vinjamuri S COVID-19: Guidance for infection prevention and control in nuclear medicine. British Nuclear Medicine Society. bnms.org.uk

23. Mossa-Basha M, Meltzer CC, Kim DC, et al. Radiology Department Preparedness for Covid--19: Radiology Scientific Expert Panel. Radiology 2020 doi: 10.1148/radiol.2020200988

24. Kooraki S, Hosseiny M, Myers L, et al. Coronavirus (Covid--19) Outbreak: What the Department of Radiology Should Know. Journal of the American College of Radiology: JACR 2020 doi: 10.1016/j.jacr.2020.02.008 [published Online First: 2020/02/25]
25. Alvin MD, George E, Dend F et al. The Impact of COVID-19 on Radiology Trainees. Radiology March 2020 https://doi.org/10.1148/radiol.2020201222

26. World Health Organization. Basic protective measures against the new coronavirus. 2020:1–23 (COVID-19). February 27, https://apps.who.int

27. Babdirali M, Sconfienza LM, Serra R et al. Chest X-ray findings in asymptomatic and minimally symptomatic quarantined patients in Codogno, Italy. Radiology. Published Online: Mar 27; 2020 https://doi.org/10.1148/radiol.2020201102

28. Wong HYF, Lam HYS, Fong AH et al. Frequency and Distribution of Chest Radiographic Findings in COVID-19 Positive Patients. Radiology Published Online: Mar 27; 2020 https://doi.org/10.1148/radiol.2020201160

29. Guidance-COVID-19: cleaning in non-healthcare settings - GOV.UK. www.gov.uk

30. BSTI COVID-19 template cation cards. BSTI COVID-19 collected resources: https://www.bsti.org.uk/covid-19-resources/

31. Chung M, Bernheim A, Mei X et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology 2020 February 4 (Epub ahead of print), doi: 10.1148/radiol.2020200230

32. Bernheim A, Mei Xueyan, Huang M et al. Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. Radiology. doi:10.1148/radiol.2020200463. Published online February 2020. © Radiological society of North America.

33. Hosseiny M, Kooraki S, Gholamrezanezhad A et al. Radiology Perspective of Coronavirus disease 2019 (COVID-19): Lessons from severe acute respiratory syndrome and Middle east respiratory syndrome American Journal of Roentgenology: 1-5. 10.2214/AJR.20.22969

34. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, Ji W. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. Radiology 2020. Doi: 10.1148/radiol.2020200432. Published February 19, 2020. Accessed February 29, 2020. Link, Google Scholar

35. Kanne JP, Little BP, Chung JH, Elicker BM, Ketail LH. Essentials for Radiologists on COVID-19: An Update—Radiology Scientific Expert Panel. Radiology 2020. Doi: 10.1148/radiol.2020200527. Published February 27, 2020. Accessed February 27, 2020.

36. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology 2020. Doi: 10.1148/radiol.2020200642. Published February 26, 2020. Accessed March 1, 2020
37. Pan F, Ye T, Sun P et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. **Radiology** 2020 February 13 (Epub ahead of print), doi: 10.1148/radiol.2020200370.

38. Bai HX, Hsieh B, Xiong Z et al Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT **Radiology** 2020. https://doi.org/10.1148/radiol.2020200823

39. BSTI COVID-19 Guidance for the reporting radiologist resources: www.bsti.or.uk

40. Albano D, Bertagna F, Bertolia M, et al Incidental findings suggestive of COVID-19 in asymptomatic patients undergoing nuclear medicine procedures in a high prevalence region **J Nucl Med.** 2020 Apr 1. pii: jnumed.120.246256. doi: 10.2967/jnumed.120.246256. [Epub ahead of print]

41. Song Y and Lan X, American College of Nuclear Medicine. https://s3.amazonaws.com/rdcms-snmmi/files/production/public/ACNM/ACNM%20COVID19%20-%20Wuhan%20NucMed%20Experience.pdf
ROUTINE ASYMPTOMATIC PATIENTS

Vetting requests & appointments
Assess clinical indication. Postpone scans to a later date unless clinical indicated (Table 2-4). Inform clinical team and patients

ASYMPTOMATIC PATIENTS-CLINICALLY URGENT SCANS

Arrival at the reception
Initial risk assessment of the patient should take place by phone. Screen patients and visitors before they enter the department. Instruct patient and accompanying relative/escort to wear masks.

Waiting area
Make them wait in the clean waiting. Instruct them not to walk around. Maintain 2 metre (6ft) distance between patients.

Radiotracer injection
Wear PPE before entering room. Dispose all items used for radiotracer injection in the designated bag/container. Disinfect the surface/equipment. Wash hands thoroughly.

Scanning room
Wear PPE as instructed. Instruct patient to wear mask during imaging.

After completion of scan
Patient leaves the department as soon as possible. Disinfect the surface and equipment after imaging. Dispose all items used in the scanning room in the designated bag/container. Wash hands thoroughly.

SUSPECTED COVID-19 PATIENTS

Vetting requests & appointments
Assess clinical indication. Postpone scans to a later date unless clinical indicated (Table 2-4). Inform clinical team and patients

SUSPECTED OR CONFIRMED COVID-19 PATIENTS WITH CLINICALLY URGENT SCANS

Vetting request & appointments
Consult clinical team and have a contingency plan in place (PPE, tracer injection, scanning protocol, disinfection, time spent in the department and post scan departure etc.). Plan to schedule the study at the end of the routine day list if a dedicated camera or waiting area is not available.

Arrival at the reception & waiting area
Allocate designated waiting room and try to inject the tracer in the same room. Instruct patient not leave the room. Instruct patient to wear mask. Wear PPE before entering room. Wash hands after injection. Disinfect the surfaces (injection chair) once the patient moves to the scanning room.

If radiotracer injection is performed in the injection room
Wear PPE before entering room. Dispose all items used for radiotracer injection in the designated bag/container. Disinfect the room/ surface/equipment. Wash hands thoroughly.

Scanning room
Wear PPE as instructed. Instruct patient to wear mask during imaging.

After completion of scan
Patient should be advised to leave the department as soon as possible once the scan is completed (out-patient). Arrange transport to take the patient back to the ward if he/she is an in-patient. Disinfect the surface and equipment after imaging. Dispose all items used in the scanning room in the designated bag/container. Wash hands thoroughly. Replace the disposable material required in the scanning room.

CONFIRMED COVID-19 PATIENTS

Vetting requests & appointments
Assess clinical indication. Postpone scans to a later date unless clinical indicated (Table 2-4). Inform clinical team and patients

Figure 1. Basic contingency for Nuclear Medicine Imaging [adapted from Yangmeihui Song and Xioli Lan, American College of Nuclear Medicine (41)]
Figure 2: An axial CT image obtained without intravenous contrast in a 36-year-old male (Panel A) shows bilateral ground-glass opacities in the upper lobes with a rounded morphology (arrows). An axial CT image obtained in a 44-year-old male (Panel B) shows larger ground glass opacities in the bilateral lower lobes with a rounded morphology (arrows). An axial CT image obtained in a 65-year-old female (Panel C) shows bilateral ground-glass and consolidative opacities with a striking peripheral distribution[32]. Reproduced with Permission: Bernheim A, Mei Xueyan, Huang M et al Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. Radiology. doi:10.1148/radiol.2020200463. Published online February 2020.© Radiological society of North America.

Figure 2: An axial CT image obtained without intravenous contrast in a 56-year-old female shows ground-glass opacities with a rounded morphology (arrows) in the right middle and lower lobes. The left lung was normal [32]. Reproduced with Permission: Bernheim A, Mei Xueyan, Huang M et al Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. Radiology. doi:10.1148/radiol.2020200463. Published online February 2020.© Radiological society of North America.
Figure 4: An axial CT image obtained without intravenous contrast in a 42-year-old male in the “late” time group (10 days from symptom onset to this CT) shows bilateral consolidative opacities, with a striking peripheral distribution in the right lower lobe (solid arrows), and with a rounded morphology in the left lower lobe (dashed arrow)[32]. Reproduced with Permission: Bernheim A, Mei Xueyan, Huang M et al Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. Radiology. doi:10.1148/radiol.2020200463. Published online February 2020.© Radiological society of North America.

Figure 5: An axial CT image obtained without intravenous contrast in a 43 year old female (Panel A) shows a “crazy-paving” pattern as manifested by right lower lobe ground-glass opacification with interlobular septal thickening (arrows) with intralobular lines. An axial CT image obtained in a 22-year old-female (Panel B) shows an area of faint ground-glass opacification in the left upper lobe with a ring of denser consolidation (arrow, “reverse halo” sign)[32]. Reproduced with Permission: Bernheim A, Mei Xueyan, Huang M et al Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. Radiology. doi:10.1148/radiol.2020200463. Published online February 2020.© Radiological society of North America.
| Managing Nuclear Medicine Department | For Nuclear Medicine Staff | For Patients attending Nuclear Medicine centre |
|--------------------------------------|---------------------------|-----------------------------------------------|
| Promote and practice social distancing (2 metres or 6 Feet) | Training in infection control | Screen patients and visitors before they enter the department |
| Risk assessment should be taken at local level with local context taken into consideration (should not replace of reduce the ability to provide optimal patient or staff safety) | Promote and practice Social Distancing (2 metres or 6 feet) | Initial risk assessment of the patient where possible should take place by phone |
| Coordination and transmission of information between Hospital information control and nuclear medicine departments | Minimize crowding in workplace (e.g. tea or lunch breaks) | Request patients to Inform nuclear medicine department (if patient or family members develop symptoms prior to the scheduled appointment) |
| Write to referring clinicians to clearly mention urgent or non-urgent scans while requesting for a scan | Maintain 6 feet (2 meters) distance in all patient/staff interactions when possible | Display posters to promote hand washing and good respiratory hygiene measures on arrival in the reception area within the department |
| Training for all staff members to ensure maximum compliance and vigilance in line with the local guidance | Should consider need for contact and droplet precautions (based on the nature of task being undertaken) | Promote Social Distancing (2 metres or 6 feet) |
| Provide clear guidance for staff to deal when patient COVID-19 status is unknown and COVID-19 is circulating at high levels | Practice strict hand hygiene which should be extended to exposed forearms, after removing any element of PPE | Recommend patient use of fluid-resistant surgical face mask (to minimise the dispersal of respiratory secretions, reduce both direct transmission risk and environmental contamination) |
| Establish local Policy to Reschedule non-urgent appointments | Should have access to the personal protective equipment (PPE) | Request patients to maintain strict hand hygiene |
| Display posters to promote hand washing and good respiratory hygiene measures within the department | Training on donning and doffing PPE | Request patients to minimize accompanying visitors/patient escorts |
| Allocate or make provision for separate space for patients with suspected or known COVID-19 infection status. | Appropriate PPE should be put on prior to providing care | Give them telehealth option (teleclinics to provide reassurance and guidance) |
| Develop clear escalation pathway to ensure cases are identified in a timely manner and triaged | Should know what PPE they should wear for each setting and context | Inform and reschedule non-urgent appointments |
| Implement a stringent local hospital policy for screening staff, patients and visitors before they enter the department | Adopt single use policy of gloves and aprons | Inform and reschedule elective therapies |
| Implement stringent local hospital policy to Minimize non-essential visitors into the department | Should take regular breaks and rest periods | Patient should spend minimum time in the department (do not allow patients to wait for long periods in the waiting area) |
| Provide PPE for staff and patients (due to concern of asymptomatic transmission of COVID-19) | Staff at all levels should remain connected with each other or with their friends and families via group email or in-portals/social media | |
Table 1 Consensus guidance for nuclear medicine departments, staff and patients (6,17, 20-25). These are examples based on consensus only and responsibility lies with each institution or hospitals to ensure their written policy adheres to that outlined by National Public Health Guidance in their respective countries and hospitals.
Planar, SPECT & SPECT-CT procedures
Referrals must be reviewed by Nuclear Medicine Consultant

| Planar, SPECT & SPECT-CT procedures | Scans to be booked and performed as requested (except patient is at risk of infection) | Liaise with the clinical team to cancel or reschedule (inform the patient) | Postpone/reschedule (inform the patient and the clinical team) |
|-------------------------------------|----------------------------------------------------------------------------------|------------------------------------------------------------------|---------------------------------------------------------------|
| **Skeletal**                        | Bone scan in cancer patients                                                    | Severe pain Pre and post procedural orthopaedic indications (? Infection, offer FDG PET-CT as alternate solution) | Pre and post procedure orthopaedic indications Metabolic bone disease Inflammatory arthropathy |
| **Endocrine**                       | 99mTc04 thyroid scans not on antithyroid medications or? ectopic/neonatal hypothyroidism | 99mTc04 thyroid scans on antithyroid medications 99mTc-MIBI parathyroid scan for pre-op localisation | |
| **Cardiovascular**                  | Myocardial Perfusion scan -Recent acute coronary syndrome (moderate to high risk patients) for urgent coronary revascularization New or increasing chest pain Pe-operative assessment (moderate to high risk patients) MUGA scan- Oncology patients (prior to initiation or prior to subsequent chemotherapy) | Myocardial Perfusion scan-awaiting liver transplant surgery Stable angina -Follow up evaluation Cardiac Amyloid DPD scan | 123I-mBG heart scan Myocardial Perfusion scan-awaiting renal transplant surgery Cardiac Amyloid DPD scan- Follow up evaluation |
| **Brain**                           | DaTSCAN (123I-FP-CIT or 123I-β-CIT-FP)                                           | VQ scan for Pulmonary Hypertension/chronic PE on treatment VQ scan? resolution of PE (patient’s on Thromboprophylaxis) | |
| **Respiratory**                     | Lung Perfusion scan in Pregnant patients Lung shunt study for 90Y-SIRT           | VQ scan for Pulmonary Hypertension/chronic PE on treatment VQ scan? resolution of PE (patient’s on Thromboprophylaxis) | Gastric emptying Oesophageal transit scintigraphy Gastro-Oesophageal reflux scintigraphy SeHCAT Small bowel/colonic transit |
| **Gastrointestinal**                | Gastrointestinal (GI) bleed Meckel’s scan                                        | HIDA scan-? acute cholecystitis                                 | Liver/spleen scan HIDA scan -cystic duct syndrome/ sphincter of Oddi dysfunction etc Liver SPECT- Haemangioma 99mTc-Denatured RBC scan |
| **Hepatobiliary**                   | HIDA scan-Biliary leak                                                           | HIDA scan-? acute cholecystitis                                 | Liver/spleen scan HIDA scan -cystic duct syndrome/ sphincter of Oddi dysfunction etc Liver SPECT- Haemangioma 99mTc-Denatured RBC scan |
| **Genitourinary**                   | 99mTc-DMSA (radiotherapy to abdomen) or prior renal surgery. 99mTc-MAG3 for urinary leak or transplant rejection Testicular scan for torsion | MAG3 for? obstruction DMSA scan- Donor assessment 99mTc-MAG3 routine follow up 99mTc-DMSA follow up evaluation Captopril renogram | |
| **Infection/inflammation**          | ? sepsis (COVID-19 negative)-suggest FDG PET-CT ? Infection of prosthesis        |                                                                 | |
| **Lymphatic system**                | Sentinel lymph node injections and imaging                                        | Lymphoscintigram for ? lymphodema                                | |
| **Oncology**                        | Octreotide/Tektrotyd prior PRRT                                                  | Octreotide/Tektrotyd for NET 123I-mIBG Pheochromocytoma/paraganglioma | |
| **Miscellaneous**                   | GFR Oncology patients (prior to initiation or prior to subsequent chemotherapy) |                                                                 | Dacroscentigraphy Salivary gland scintigraphy DXA scan |

Table 2. Scheduling Nuclear Medicine Procedures (SPECT tracers). Kindly note:
Referrals must be reviewed by Nuclear Medicine Consultants or Multidisciplinary setting). These are examples based on consensus only and responsibility lies with each institution or hospitals to ensure their written policy adheres to that outlined by National Public Health Guidance in their respective countries and hospitals.
**PET-CT**
Referrals must be reviewed by Nuclear Medicine Consultant

| Scans to be booked and performed as requested (except patient is at risk of infection) | Liaise with the clinical team to cancel or reschedule (Inform the patient) |
|---|---|
| **Oncology** | 18F-FDG PET-CT: Follow-up evaluation |
| 18F-FDG PET-CT: Staging; restaging; response assessment etc) | 68Ga-DOTATATE/DOTATOC: follow up evaluation |
| 18F-FDG PET-CT: radiotherapy planning | 18F-PSMA or 68Ga-PSMA: follow up evaluation |
| 18F-PSMA or 68Ga-PSMA: Biochemical recurrence | 18F-Choline: follow up evaluation |
| 18F-Choline: Biochemical recurrence | 18F-NaF: follow up evaluation |
| 68Ga-DOTATATE/DOTATOC: staging, restaging and selecting patients for PRRT | 18F-DOPA: follow up evaluation |
| 18F-NaF: Bone metastases |  |
| 18F-DOPA: diagnosis and staging |  |
| **Non-oncology** |  |
| 1. 18F-FDG PET-CT: pyrexia of unknown origin (COVID-19 negative) | 18F-FDG PET-CT: known Sarcoidosis on treatment |
| 2. 18F-FDG PET-CT: Sepsis | 18F-FDG PET-CT: Polymyalgia rheumatica |
| 3. 18F-FDG PET-CT (viability): symptomatic patients awaiting CABG | 18F-FDG PET-CT: known cardiac sarcoidosis on treatment (follow up evaluation) |
| 4. 18F-FDG PET-CT: Suspected device or prosthetic infection |  |
| 5. 18F-FDG: cardiac sarcoidosis |  |

**Table 3: Scheduling Patients for PET-CT studies**

*Kindly note These are examples based on consensus only and responsibility lies with each institution or hospitals to ensure their written policy adheres to that outlined by National Public Health Guidance in their respective countries and hospitals. (20-22)*
Referrals must be reviewed by Nuclear Medicine Consultant
Each patient needs to be assessed on an individual basis by the clinical team/MDT

| Referrals must be reviewed by Nuclear Medicine Consultant Each patient needs to be assessed on an individual basis by the clinical team/MDT | Referrals must be reviewed by Nuclear Medicine Consultant Each patient needs to be assessed on an individual basis. [Liaise with the clinical team or MDT to cancel or reschedule (Inform the patient)] |
|---|---|
| **177Lutetium–DOTATATE Peptide Receptor Radionuclide Therapy (PRRT)- Metastatic Neuroendocrine tumours** (Consider marrow depletion post procedure) | **131I (radioiodine) -thyroid cancer** (kindly follow the thyroid cancer management guide for various risk categories) |
| **Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT)-HCC or liver metastases** | **131I(radioiodine) -benign thyroid disease**
Most patients can be postponed (Consideration should be given to patients who are unable to tolerate anti-thyroid medication). |
| **131I-Meta-iodobenzylguanidine (mIBG) therapy- Metastatic Pheochromocytoma/paraganglioma** | **Radiosynovectomy-arthritis, haemophilia etc** |
| **177Lutetium–prostate specific membrane antigen (PSMA)- Metastatic Prostate cancer** | **225Actinium-Prostate specific membrane antigen (PSMA)- Metastatic Prostate cancer** (Consider co-morbidities ) |
| **223-Radium- Prostate cancer (skeletal metastases)** | **223-Radium- Prostate cancer (skeletal metastases)** |

**Table 4: Scheduling patients for radionuclide therapy:**
*Kindly note: Referrals must be reviewed by Nuclear Medicine Consultants or Multidisciplinary setting). These are examples based on consensus only and responsibility lies with each institution or hospitals to ensure their written policy adheres to that outlined by National Public Health Guidance in their respective countries and hospitals. (20,22)*
Coronavirus (COVID-19) Pandemic: What the Nuclear Medicine Departments Should Know

Gopinath Gnanasegaran, Jessica Williams, Hian Liang Huang and Jamshed B. Bomanji

*J. Nucl. Med. Technol.*
Published online: April 20, 2020.
Doi: 10.2967/jnmt.120.247296

This article and updated information are available at: [http://tech.snmjournals.org/content/early/2020/04/17/jnmt.120.247296.citation](http://tech.snmjournals.org/content/early/2020/04/17/jnmt.120.247296.citation)

Information about reproducing figures, tables, or other portions of this article can be found online at: [http://tech.snmjournals.org/site/misc/permission.xhtml](http://tech.snmjournals.org/site/misc/permission.xhtml)

Information about subscriptions to JNMT can be found at: [http://tech.snmjournals.org/site/subscriptions/online.xhtml](http://tech.snmjournals.org/site/subscriptions/online.xhtml)

*JNMT* ahead of print articles have been peer reviewed and accepted for publication in *JNMT*. They have not been copyedited, nor have they appeared in a print or online issue of the journal. Once the accepted manuscripts appear in the *JNMT* ahead of print area, they will be prepared for print and online publication, which includes copyediting, typesetting, proofreading, and author review. This process may lead to differences between the accepted version of the manuscript and the final, published version.

*Journal of Nuclear Medicine Technology* is published quarterly.
SNMMI | Society of Nuclear Medicine and Molecular Imaging
1850 Samuel Morse Drive, Reston, VA 20190.
(Print ISSN: 0091-4916, Online ISSN: 1535-5675)

© Copyright 2020 SNMMI; all rights reserved.